Ameriprise Financial Inc Caribou Biosciences, Inc. Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.82 - $8.26 $19 - $33	4 Added 0.01%	36,555 $187,000
Q4 2023 Feb 14, 2024	SELL	$3.58 - $6.25 $20,853 - $36,406	-5,825 Reduced 13.75%	36,551 $209,000
Q3 2023 Nov 14, 2023	SELL	$4.08 - $8.14 $238,659 - $476,149	-58,495 Reduced 57.99%	42,376 $202,000
Q2 2023 Aug 14, 2023	BUY	$4.04 - $5.47 $255,000 - $345,260	63,119 Added 167.19%	100,871 $428,000
Q1 2023 May 15, 2023	BUY	$4.3 - $7.78 $3,762 - $6,807	875 Added 2.37%	37,752 $200,000
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $7,324 - $14,478	-1,315 Reduced 3.44%	36,877 $231,000
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $203,945 - $488,475	38,192 New	38,192 $403,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $119M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.